Related Pages for DRREDDY
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
DRREDDY
Related News - DRREDDY
Dr. Reddy's Laboratories: Co Gets DCGI Approval For Zytorvi® (Toripalimab) For Advanced Esophageal Squamous Cell Carcinoma; This Marks The Second Approved Use In India, Expanding Beyond Nasopharyngeal Carcinoma; Clinical Trials Indicate A 42% Decrease In Risk Of Disease Or Death.
21 Oct 2026 09:41 AM
Dr. Reddy's Laboratories: Co Gets DCGI Approval For Zytorvi® (Toripalimab) For Advanced Esophageal Squamous Cell Carcinoma; This Marks The Second Approved Use In India, Expanding Beyond Nasopharyngeal Carcinoma; Clinical Trials Indicate A 42% Decrease In Risk Of Disease Or Death.
Dr. Reddy's Laboratories: Co CFO Is Sure About "High-Teen" Revenue Growth For FY27 And Later; The Company Has The Ability To Acquire Up To $2B In "Strategic Assets" And Is Aiming To Buy Firms And Brands Across Various Therapies.
29 Sep 2026 03:06 PM
Dr. Reddy's Laboratories: Co CFO Is Sure About "High-Teen" Revenue Growth For FY27 And Later; The Company Has The Ability To Acquire Up To $2B In "Strategic Assets" And Is Aiming To Buy Firms And Brands Across Various Therapies.
Dr Reddy's: CFO Expresses Interest In Acquiring Any Size Of Companies, Emphasizing The Importance Of The Right Assets.
29 Sep 2026 03:07 PM
Dr Reddy's: CFO Expresses Interest In Acquiring Any Size Of Companies, Emphasizing The Importance Of The Right Assets.
Dr. Reddy's Laboratories: Unveils New Products To Boost Growth; Targets 25% EBITDA Margin Long-Term And 20% For FY27.
29 Sep 2026 03:07 PM
Dr. Reddy's Laboratories: Unveils New Products To Boost Growth; Targets 25% EBITDA Margin Long-Term And 20% For FY27.
Dr Reddy's: Company's Co CFO Highlights Plans to Submit New PDT Applications in Emerging Markets; Nicotine Products Expected to Boost Sales in Europe by FY27.
29 Sep 2026 03:08 PM
Dr Reddy's: Company's Co CFO Highlights Plans to Submit New PDT Applications in Emerging Markets; Nicotine Products Expected to Boost Sales in Europe by FY27.
Dr. Reddy's Laboratories: Sees Growth Potential With 3 Complex Generic Products In The US; Plans To Introduce 20-25 New Products In FY27; Anticipates Strong US Sales Growth For FY27
29 Sep 2026 03:08 PM
Dr. Reddy's Laboratories: Sees Growth Potential With 3 Complex Generic Products In The US; Plans To Introduce 20-25 New Products In FY27; Anticipates Strong US Sales Growth For FY27
Dr Reddy’s: Nomura on Dr Reddy’s Buy, Target Price ₹1,740, as the company awaits USFDA clearance/EIR for its biologics plant and Abatacept IV approval by Dec 18, 2026; management expects a positive outcome, supported by recent Rituximab approval and validated commercial-scale batches, with sufficient capacity and no scale-up concerns; sees strong medium- to long-term biosimilar opportunities from patent expiries and easing regulation.
28 Sep 2026 08:59 AM
Dr Reddy’s: Nomura on Dr Reddy’s Buy, Target Price ₹1,740, as the company awaits USFDA clearance/EIR for its biologics plant and Abatacept IV approval by Dec 18, 2026; management expects a positive outcome, supported by recent Rituximab approval and validated commercial-scale batches, with sufficient capacity and no scale-up concerns; sees strong medium- to long-term biosimilar opportunities from patent expiries and easing regulation.
Dr. Reddy’s Laboratories: Plans Meeting With Analysts And Investors On September 25
21 Sep 2026 05:47 PM
Dr. Reddy’s Laboratories: Plans Meeting With Analysts And Investors On September 25
Dr. Reddy’s Labs: Takeda and Co. Team Up to Market Qdenga, India’s First Approved Dengue Vaccine for Kids and Adults.
18 Sep 2026 09:08 AM
Dr. Reddy’s Labs: Takeda and Co. Team Up to Market Qdenga, India’s First Approved Dengue Vaccine for Kids and Adults.
Dr Reddy's Labs:Co. Agrees To Licensing Deal With Gilead For Once-Yearly Lenacapavir To Prevent HIV.
18 Sep 2026 08:48 AM
Dr Reddy's Labs:Co. Agrees To Licensing Deal With Gilead For Once-Yearly Lenacapavir To Prevent HIV.
Dr Reddy's: Enters Royalty-Free License Agreement With Gilead For Annual Lenacapavir HIV Prevention.
17 Sep 2026 03:29 PM
Dr Reddy's: Enters Royalty-Free License Agreement With Gilead For Annual Lenacapavir HIV Prevention.
Dr. Reddy’s Labs: USFDA Finishes Inspection At Dr. Reddy’s Labs Facility In Morelos, Mexico Receives Two Observations In Form FDA 2953
12 Sep 2026 10:09 AM
Dr. Reddy’s Labs: USFDA Finishes Inspection At Dr. Reddy’s Labs Facility In Morelos, Mexico Receives Two Observations In Form FDA 2953
Drugmakers May Soon Need To Clearly Label Medicines As Synthetic Or Biological Under New Rules - Mint ( Biocon, Dr. Reddy, Zydus ) - Newspaper
02 Sep 2026 09:13 AM
Drugmakers May Soon Need To Clearly Label Medicines As Synthetic Or Biological Under New Rules - Mint ( Biocon, Dr. Reddy, Zydus ) - Newspaper
India Preps New Semaglutide Standards For Manufacturing & Testing As Rising Weight-loss Drug - Newspaper ( Dr Reddy’s, Biocon, Sun Pharma, Zydus Lifesciences & Lupin )
24 Aug 2026 09:13 AM
India Preps New Semaglutide Standards For Manufacturing & Testing As Rising Weight-loss Drug - Newspaper ( Dr Reddy’s, Biocon, Sun Pharma, Zydus Lifesciences & Lupin )
HC orders cancelling Razenta Pharma's Daplogin trademark on Dr Reddy's plea
20 Aug 2026 12:44 PM
HC orders cancelling Razenta Pharma's Daplogin trademark on Dr Reddy's plea
Dr. Reddy's: Launches First Generic Version Of Sugammadex Injection In The U.S.
04 Aug 2026 11:14 AM
Dr. Reddy's: Launches First Generic Version Of Sugammadex Injection In The U.S.
Dr. Reddy's Laboratories: Co Gets U.S. FDA Green Light For Rituximab Biosimilar; Fresenius Kabi To Exclusively Sell It In The U.S.; Approval Boosts Global Biosimilars Collection.
01 Aug 2026 11:38 AM
Dr. Reddy's Laboratories: Co Gets U.S. FDA Green Light For Rituximab Biosimilar; Fresenius Kabi To Exclusively Sell It In The U.S.; Approval Boosts Global Biosimilars Collection.
Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.
30 Jul 2026 09:20 AM
Dr. Reddy's: Expects Strong Performance In Q3 And Q4 After Fixing Semaglutide Problems.
DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)
27 Jul 2026 02:40 PM
DR Reddy's: Receives Approval From Thai FDA For Nuzolvance (Zolifloxacin)
Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update
23 Jul 2026 09:06 AM
Dr Reddy's Laboratories: Guidance - Management maintains its guidance for EBITDA margin to be in the neighborhood of 20% for the next quarter, even without semaglutide, and expects higher margins with semaglutide resumption in November.- Comcall Update
